KOREA WHO
-
-
CEO & President, HK inno.N
Kwak Dal-won
K-CAB Goes Global, Revenue Tops KRW 1 Trillion (US$719.4 Million)
-
Last Updated on Nov 10, 2026
-
CEO & President, HK inno.N
Copy Url : https://www.koreawho.com/profile/KwakDalwon- Life Summary
Kwak Dal-won is president and CEO of HK inno.N.
He is expanding the health functional food and health and beauty businesses while pushing to enter the contract development and manufacturing (CDMO) business for biopharmaceuticals.
He was born on May 13, 1960.
He graduated from Kyungbock High School in Seoul and Sungkyunkwan University with a degree in business administration. He completed an MBA program at Sungkyunkwan University's Graduate School of Business.
After joining Samsung Group, he worked in the pharmaceutical division of CJ Cheiljedang as head of the Yeongnam Regional Sales Department, head of the Sales Support Team, and head of the Second Business Division.
When CJ Cheiljedang's pharmaceutical division became an independent company called CJ Healthcare in 2014, he was appointed co-CEO.
After CJ Healthcare was acquired by Kolmar Korea and renamed HK inno.N, he served as head of the Ethical Drug Business and head of Production before being appointed CEO in 2022.
#KwakDalwon #HKinnoN #CEO #CJHealthcare #CJCheiljedang #PharmaceuticalIndustry #Biopharmaceuticals #CDMO #ExecutiveProfile #BusinessLeadership
He is expanding the health functional food and health and beauty businesses while pushing to enter the contract development and manufacturing (CDMO) business for biopharmaceuticals.
He was born on May 13, 1960.
He graduated from Kyungbock High School in Seoul and Sungkyunkwan University with a degree in business administration. He completed an MBA program at Sungkyunkwan University's Graduate School of Business.
After joining Samsung Group, he worked in the pharmaceutical division of CJ Cheiljedang as head of the Yeongnam Regional Sales Department, head of the Sales Support Team, and head of the Second Business Division.
When CJ Cheiljedang's pharmaceutical division became an independent company called CJ Healthcare in 2014, he was appointed co-CEO.
After CJ Healthcare was acquired by Kolmar Korea and renamed HK inno.N, he served as head of the Ethical Drug Business and head of Production before being appointed CEO in 2022.
#KwakDalwon #HKinnoN #CEO #CJHealthcare #CJCheiljedang #PharmaceuticalIndustry #Biopharmaceuticals #CDMO #ExecutiveProfile #BusinessLeadership
- Life Summary
- Career Highlights & Challenges
- · Enters Medical Device Business with Roche Diagnostics Korea
- · Expands K-CAB's Global Business
- · K-CAB Seeks US New Drug Approval
- · Revenue Tops KRW 1 Trillion (US$719.4 Million), Profitability Improves
- · Expands Hangover Relief Product Lineup
- · Completes Korean Atopic Dermatitis Phase 2, Pursues US Development
- · Seeks Approval for Canine Atopic Dermatitis Treatment
- · Opens HK inno.N Square, Consolidates R&D Capabilities in Pangyo
- · Pursues Corporate Value Enhancement Plan
- · Completes Patient Recruitment for Phase 3 Obesity Trial
- · Boryung Replaces Chong Kun Dang Pharm as K-CAB Partner
- · Launches Zero-Calorie Iced Tea TEALOG
- · Halts In-House Cell and Gene Therapy Research
- · Invests in IV Fluid Production, Expands High-Value Products
- · Pursues Overseas Expansion of Condition Hangover Relief Drink
- · Leads Pharmaceutical Division and Becomes HK inno.N CEO
- · Acquired by Kolmar Korea
- · HK inno.N's Corporate History
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- - Eight-Beverage Recall; KRW 3 Billion (US$2.2 Million) Compensation
- - Controversy over Security App on Personal Phones
- - Defends K-CAB Compound Patent, Loses Crystal Form Patent Challenge
- - Advertising Suspension for Claims Beyond Diabetes Drug Approvals
- - CJ Healthcare Drug Price Reduction Penalty and Lawsuit
- - CJ Cheiljedang Pharmaceutical Executives Convicted of Illegal Rebates
- Professional Timeline
- Educational Background
- Additional Information
- Notable Quotations
- Infographic & Photos